Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Hoffmann who wrote (268)	4/25/1999 9:46:00 PM
From: Micro-Selector	Read Replies (1) \| Respond to of 307

Thanks for the clarification. I assume an "insider" includes only current employees and therefore Araminta Wade, as a "former employee," would not qualify? Was A. Wade an employee at the time of sale? When R. Nicora reported that these were not "true insiders," I assumed that many of the "planned sales" must have been made by former employees affiliated with or loyal to the previous CEO and that some degree of turnover and insider sell-off had resulted from his resignation. Is this completely off base? Any opinion on the long-term prospects for SYBD or the pending funding? Thanks, Micro